{"pmid":32453251,"title":"Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.","text":["Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.","Shock","Napp, L Christian","Bauersachs, Johann","32453251"],"journal":"Shock","authors":["Napp, L Christian","Bauersachs, Johann"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453251","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/SHK.0000000000001568","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667983494592069633,"score":9.490897,"similar":[{"pmid":32482373,"title":"Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","text":["Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.","Arch Med Res","Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib","32482373"],"abstract":["Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab."],"journal":"Arch Med Res","authors":["Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.arcmed.2020.05.009","keywords":["covid-19","cytokine storm syndrome","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532114882035712,"score":64.7701},{"pmid":32376400,"title":"Cytokine storm syndrome in severe COVID-19.","text":["Cytokine storm syndrome in severe COVID-19.","Autoimmun Rev","Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto","32376400"],"journal":"Autoimmun Rev","authors":["Ruscitti, Piero","Berardicurti, Onorina","Iagnocco, Annamaria","Giacomelli, Roberto"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376400","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102562","locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097403580416,"score":56.68499},{"pmid":32425294,"pmcid":"PMC7227559","title":"Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","text":["Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.","Blood Rev","England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C","32425294"],"abstract":["A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS."],"journal":"Blood Rev","authors":["England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425294","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.blre.2020.100707","keywords":["covid-19","cytokine release syndrome","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","idiopathic multicentric castleman disease","severe acute respiratory syndrome coronavirus -2 (sars-cov-2)"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837925519360,"score":52.486423},{"pmid":32352407,"title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","text":["Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.","J Clin Invest","Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan","32352407"],"abstract":["Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases."],"journal":"J Clin Invest","authors":["Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352407","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1172/JCI139642","e_drugs":["Catecholamines"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495698075648,"score":49.072067},{"pmid":32283152,"pmcid":"PMC7194613","title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","text":["The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.","J Infect","Ye, Qing","Wang, Bili","Mao, Jianhua","32283152"],"abstract":["Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment."],"journal":"J Infect","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283152","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.037","keywords":["2019-ncov","coronavirus","cytokine storm","immunomodulation","sars-cov-2"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491454488580,"score":47.96927}]}